Myocardial Infarction Market
Global Myocardial Infarction Market Size, Share & Trends Analysis Report By Type (NSTEMI, STEMI, and Silent Heart Attacks) By Device (Left Ventricular Assist Device, Pacemaker, Catheters, Implantable Cardioverter Defibrillator, and Others) By Diagnosis (ECG, Chest X-Ray, Computed Tomography (CT Scan), Echocardiography, and Others ) By Treatment (Medication, and Surgery) By End-Users (Hospitals and Clinics, Ambulatory Surgical Centers, and Research Institutes) Forecast 2021-2027
The global myocardial infarction market is anticipated to grow at a modest CAGR of around 6.6% during the forecast period. The global myocardial infarction market is primarily driven by the increasing incidence and prevalence rate of chronic diseases, such as diabetes and hypertension along with unhealthy lifestyle changes such as suboptimal diets, excessive consumption of tobacco consumption and alcohol, and sedentary lifestyles. According to WHO, there is an increased risk of myocardial infarction in individuals with smoking habits. The global rise in smokers has increased the risk of heart diseases, it is anticipated to create demand for the myocardial infarction market. According to the Centers for Disease Control and Prevention (CDC), in 2018, nearly 14 of every 100 US adults aged 18 years or older (13.7%) smoked cigarettes. This means an estimated 34.2 million adults in the US currently smoke cigarettes.
However, the lack of health awareness in emerging economies and the high cost of medication and procedure for heart diseases may restrain the growth of the market. On the other hand, the supportive laws and schemes for the reduction and prevention of heart diseases and the rising adoption of minimally invasive treatment are anticipated to create the future opportunity for the growth of the myocardial infarction market.
Segmental Outlook
The global myocardial infarction market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into non-ST segment elevation myocardial infarction (NSTEMI) heart attacks, ST-segment elevation myocardial infarction (STEMI) heart attacks, and silent heart attacks. Among these, STEMI held the highest market share in 2020 and is estimated to grow a significant CAGR during the forecast period. STEMI is the most common type of heart attack among all types. The commonly used treatment for STEMI includes percutaneous coronary intervention (PCI), a term that consists of both angioplasty and stenting; clot-busting medication; and coronary artery bypass graft surgery (CABG). Based on the device, the market is segmented into the left ventricular assist device, pacemaker, catheter, implantable cardioverter defibrillator, and others (graft and stent). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT scan), echocardiography, and others. On the basis of treatment, the market is bifurcated into medication and procedure. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
Global Myocardial Infarction Market Share by Diagnosis, 2020 (%)
The ECG Segment Is Projected to Hold the Largest Share in the Myocardial infarction Market
Based on Diagnosis, the electrocardiography (ECG) segment dominated the market in 2020 and is projected to remain dominant during the forecast period. ECG is the most commonly used technology to diagnose all types of myocardial infarction. ECG provides insights about heart rate, indicates if there is the enlargement of the heart due to high blood pressure (hypertension) or evidence of a previous heart attack (myocardial infarction). Due to the rising prevalence of chronic and cardiovascular disease, the adoption of ECG is increasing, on the other hand, the growing number of hospitals coupled with these advanced technologies is expected to increase the sales and market value.
Regional Outlook
Geographically, the global myocardial infarction market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Among these, the Asia-Pacific market is anticipated to showcase the highest CAGR during the forecast period. Increasing cases related to CVD and heart attack, increasing healthcare infrastructure, and increasing unhealthy lifestyles among people in the region are some of the major factors for the growth of the market in the region. The increasing medical tourism and improving healthcare infrastructure are also contributing significantly to the growth of the myocardial infarction market in the region. The developing economies of Asia-Pacific, especially China, Japan, and India are investing significantly in the development of innovative therapeutic and medical devices.
Global Myocardial Infarction Market Growth, by region 2021-2027
North America is projected to Dominate the Myocardial infarction Market
Geographically, North America projected to hold the highest market share in 2020, and it is anticipated to dominate the market during the forecast period. The regional market is mainly driven by high per capita healthcare expenditure, technological advancement including the development of the latest technology-based stents, rising adoption of hybrid operating rooms and increasing minimally invasive surgeries. The high cost of drugs and procedures in the US and the significant sale of branded drugs in the region are other factors contributing to the growth of the market. Further, the increasing prevalence of heart attack, FDA approvals, favorable government policies is also driving the demand for diagnosis and treatment in the region. The US is expected to make a major contribution to the myocardial infarction market due to the rise in the adoption of hybrid operating rooms and innovative treatment technology. Hospitals and clinics in the US are well equipped with the latest treatment devices which are essential to perform critical MI surgeries.
Market Players Outlook
The key players in the global myocardial infarction market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market are Koninklijke Philips N.V., Abbott Laboratories, Siemens AG, Bayer AG, Novartis AG, Boehringer Ingelheim GmbH, AstraZeneca PLC, Merck KGaA, Sanofi SA, Pfizer Inc., GSK PLC, Johnson & Johnson Services Inc., Mylan N.V., among others. To remain competitive in the market and to generate major revenue, these market players adopt different marketing strategies such as mergers and acquisitions, R&D, product launches, partnership collaboration, and geographical expansions so on. For instance, in Jan 2019, Abbott announced that it had acquired Cephea Valve Technologies, Inc., a privately-held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease. The acquisition aids Abbott to build a strong position in structural heart therapies and expanding its product offerings in comprehensive treatments for people with mitral valve disease.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global myocardial infarction market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Myocardial Infarction Industry
• Recovery Scenario of Global Myocardial Infarction Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.2. Key Strategy Analysis
3.3. Impact of Covid on key players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Myocardial Infarction Market, By Type
5.1.1. Non-St-Elevation Myocardial Infarction (NSTEMI)
5.1.2. St-Elevation Myocardial Infarction (STEMI) Heart Attack
5.1.3. Silent Heart Attack
5.2. Global Myocardial Infarction Market, By Device
5.2.1. Left Ventricular Assist Device
5.2.2. Pacemaker
5.2.3. Catheters
5.2.4. Implantable Cardioverter Defibrillator
5.2.5. Others
5.3. Global Myocardial Infarction Market, ByDiagnosis
5.3.1. Electrocardiography (ECG)
5.3.2. Chest X-Ray
5.3.3. Computed Tomography (CT scan)
5.3.4. Echocardiography
5.3.5. Others (Blood Test)
5.4. Global Myocardial Infarction Market, By Treatment
5.4.1. Medication
5.4.1.1. Analgesics
5.4.1.2. Thrombolytic
5.4.1.3. Anti-Platelet Agents
5.4.1.4. Glycoprotein LIB/LIB Inhibitors
5.4.1.5. Others (Beta-Adrenergic Blockers and Angiotensin-Receptor Blockers)
5.4.2. Surgery
5.4.2.1. Angioplasty
5.4.2.2. Coronary Artery Bypass Grafting (CABG)
5.4.2.3. Heart Transplant
5.5. Global Myocardial Infarction Market, ByEnd-Users
5.5.1. Hospitals and Clinics
5.5.2. Ambulatory Surgical Centers
5.5.3. Research Institutes
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Russia
6.2.7. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
6.4.1. Latin America
6.4.2. Middle East Africa
7. Company Profiles
7.1. Abbott Laboratories
7.2. advanceCOR GmbH.
7.3. AstraZeneca PLC
7.4. Athersys, Inc.
7.5. Bayer AG
7.6. BioVascular Inc.
7.7. Boehringer Ingelheim International GmbH
7.8. Boston Scientific Corp.
7.9. Bristol-Myers Squibb, Co.
7.10. Caladrius Biosciences, Inc.
7.11. Capricor Therapeutics Inc.
7.12. CSL Behring
7.13. Eli Lilly And Co.
7.14. GlaxoSmithKline plc.
7.15. GNT Pharma Co., Ltd.
7.16. Johnson & Johnson Services Inc.
7.17. Koninklijke Philips N.V.
7.18. Medtronic Plc
7.19. Merck KGaA
7.20. Mesoblast Ltd
7.21. Mylan N.V.
7.22. Novartis AG
7.23. NeuroVive Pharmaceutical AB
7.24. Osiris Therapeutics Inc.
7.25. Pfizer Inc.
7.26. PledPharma AB
7.27. Portola Pharmaceutical Inc.
7.28. Sanofi SA
7.29. Siemens AG
7.30. Teva Pharmaceutical Industries Ltd.
7.31. Ventrix, Inc.
1. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
2. GLOBAL NSTEMI HEART ATTACKS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
3. GLOBAL STEMI HEART ATTACKS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL SILENT HEART ATTACKS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2020-2027 ($ MILLION)
6. GLOBAL LEFT VENTRICULAR ASSIST DEVICE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL PACEMAKER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL CATHETERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATOR MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
12. GLOBAL ELECTROCARDIOGRAPHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL CHEST X-RAY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL COMPUTED TOMOGRAPHY (CT SCAN) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL ECHOCARDIOGRAPHY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
17. GLOBAL MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
18. GLOBAL SURGERY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
19. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
20. GLOBAL HOSPITAL & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
21. GLOBAL AMBULATORY SURGICAL CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
22. GLOBAL RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
23. GLOBAL MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
24. NORTH AMERICAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
25. NORTH AMERICAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
26. NORTH AMERICAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DEVICE, 2020-2027 ($ MILLION)
27. NORTH AMERICAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
28. NORTH AMERICAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
29. NORTH AMERICAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
30. EUROPEAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
31. EUROPEAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
32. EUROPEAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DEVICE, 2020-2027 ($ MILLION)
33. EUROPEAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
34. EUROPEAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
35. EUROPEAN MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
36. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
37. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
38. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DEVICE, 2020-2027 ($ MILLION)
39. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
40. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
41. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
42. REST OF THE WORLD MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
43. REST OF THE WORLD MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
44. REST OF THE WORLD MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DEVICE, 2020-2027 ($ MILLION)
45. REST OF THE WORLD MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
46. REST OF THE WORLD MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
47. REST OF THE WORLD MYOCARDIAL INFARCTION MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL MYOCARDIAL INFARCTION MARKET, 2020-2027 (% MILLION)
2. IMPACT OF COVID-19 ON GLOBAL MYOCARDIAL INFARCTION MARKET BY SEGMENT, 2020-2027 (% MILLION)
3. RECOVERY OF GLOBAL MYOCARDIAL INFARCTION MARKET, 2020-2027 (%)
4. GLOBAL MYOCARDIAL INFARCTION MARKET SHARE BY TYPE, 2020 VS 2027 (%)
5. GLOBAL MYOCARDIAL INFARCTION MARKET SHARE BY DEVICE, 2020 VS 2027 (%)
6. GLOBAL MYOCARDIAL INFARCTION MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
7. GLOBAL MYOCARDIAL INFARCTION MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
8. GLOBAL MYOCARDIAL INFARCTION MARKET SHARE BY END-USERS, 2020 VS 2027 (%)
9. GLOBAL MYOCARDIAL INFARCTION MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
10. GLOBAL NON-ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI) MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) HEART ATTACK MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL SILENT HEART ATTACK MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL LEFT VENTRICULAR ASSIST DEVICE MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL PACEMAKER MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
15. GLOBAL CATHETERS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
16. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATOR MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
17. GLOBAL OTHERS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
18. GLOBAL ELECTROCARDIOGRAPHY (ECG)MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
19. GLOBAL CHEST X-RAY MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
20. GLOBAL COMPUTED TOMOGRAPHY (CT SCAN)MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
21. GLOBAL ECHOCARDIOGRAPHY MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
22. GLOBAL MEDICATION MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
23. GLOBAL SURGERY MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
24. GLOBAL HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
25. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
26. GLOBAL RESEARCH INSTITUTES MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
27. US MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
28. CANADA MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
29. UK MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
30. FRANCE MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
31. GERMANY MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
32. ITALY MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
33. SPAIN MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
34. RUSSIA MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
35. REST OF EUROPE MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
36. INDIA MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
37. CHINA MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
38. JAPAN MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
39. SOUTH KOREA MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
40. REST OF ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027 ($ MILLION)
41. REST OF THE WORLD MYOCARDIAL INFARCTION MARKET SIZE, 2020-2027($ MILLION
